Clinical Research Directory

Inclusion Criteria:1.Age: Aged ≥18 years.2.Diagnosis: Diagnosis of Crohn's disease confirmed by endoscopy and histopathology, with active disease (CDAI ≥150).3.Treatment Indication: Indicated for anti-TNF-α biologic therapy (infliximab or adalimumab) and being naive to these specific agents.4.Informed Consent: Willing and able to provide written informed consent.5.Compliance: Able to understand and comply with the study protocol requirements, including dietary intervention and follow-up schedule. \- Exclusion Criteria:1.Severe Complications: Presence of intestinal obstruction, intra-abdominal abscess, intestinal fistula, or other severe complications requiring surgical intervention.2.Comorbidities: Severe cardiac, hepatic, or renal insufficiency (e.g., Child-Pugh class C, or eGFR \<30 mL/min/1.73 m²).3.Infection Risk: Active tuberculosis, active hepatitis B, HIV infection, or other severe opportunistic infections.4.Malignancy: Current or history of malignancy, except for non-melanoma skin cancer.5.Pregnancy Status: Pregnant or breastfeeding women, or women planning pregnancy during the study period.6.Medication Use: Recent use (within 3 months) of other immunosuppressants (e.g., azathioprine, methotrexate) or corticosteroids (e.g., prednisone \>20 mg/day).7.Dietary Restrictions: Severe food allergies, celiac disease, severe malnutrition (BMI \<18.5 kg/m²), or inability to adhere to the Crohn's Disease Exclusion Diet (CDED).8.Other Factors: Concurrent participation in another clinical trial, or any other condition deemed by the investigator to make the patient unsuitable for study participation. \-